Evripidis Lanitis

Ludwig Cancer Research Lausanne Branch
Lausanne, VD, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy.

Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy.

Journal: Nature reviews. Immunology

Published: May 06, 2025

Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager.

Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager.

Journal: Journal for immunotherapy of cancer

Published: February 23, 2025

Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells.

Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells.

Journal: Nature immunology

Published: March 28, 2022

Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells.

Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells.

Journal: Human gene therapy

Published: October 18, 2021

VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding.

VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding.

Journal: Journal for immunotherapy of cancer

Published: June 07, 2021

Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.

Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.

Journal: Cell reports

Published: May 28, 2020

All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy.

All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy.

Journal: Current opinion in biotechnology

Published: December 09, 2019

miR-155 Overexpression in OT-1 CD8+ T Cells Improves Anti-Tumor Activity against Low-Affinity Tumor Antigen.

miR-155 Overexpression in OT-1 CD8+ T Cells Improves Anti-Tumor Activity against Low-Affinity Tumor Antigen.

Journal: Molecular therapy oncolytics

Published: December 03, 2019

Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression.

Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression.

Journal: The Journal of experimental medicine

Published: November 21, 2019

Correction to: CART cells are prone to Fas- and DR5-mediated cell death.

Correction to: CART cells are prone to Fas- and DR5-mediated cell death.

Journal: Journal for immunotherapy of cancer

Published: September 14, 2018

CART cells are prone to Fas- and DR5-mediated cell death.

CART cells are prone to Fas- and DR5-mediated cell death.

Journal: Journal for immunotherapy of cancer

Published: January 16, 2018

Mechanisms regulating T-cell infiltration and activity in solid tumors.

Mechanisms regulating T-cell infiltration and activity in solid tumors.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 19, 2017

Showing 1-12 of 25

Last Updated: 09/26/2026